Compare Amphastar Pharmaceuticals Inc (AMPH) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Devon Energy Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Devon Energy Corp trades at $42.62 (market cap $48.71B). The key difference: Devon Energy Corp is far larger — about 59× Amphastar Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.46% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DVN | |
|---|---|---|
Market Cap | $826.08M | $48.71B |
Sector | Health | Energy |
52-Week High | $30.81 | $52.07 |
52-Week Low | $16.87 | $31.74 |
Enterprise Value | $1.22B | $55.49B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Devon Energy (DVN) trades at $42.23, up 0.5% with neutral technical signals. The company shows strong fundamentals with a P/E of 11.76 and ROE of 15.13%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Positive sentiment includes 71% analyst buy ratings and a $60.55 consensus target, while activist investor TOMS Capital pushes for asset sales or company sale (Reuters, 2026-06-17).
DVN offers value with discounted valuation and $1B synergy potential from the Coterra merger, but faces oil price volatility and execution risks. The stock trades 30% below analyst targets, presenting upside if operational targets are met, though debt levels and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
